Mometasone Furoate

Hydroquinone, Tretinoin, and Fluocinolone Acetonide is the gold-standard Triple Combination Cream (Kligman's formula) for refractory melasma. Hydroquinone (2-4%) competitively inhibits tyrosinase, blocking melanin pigment synthesis; Tretinoin (0.05%) accelerates epidermal turnover and keratinocyte shedding, facilitating hydroquinone penetration and dispersing melanin; and Fluocinolone Acetonide (0.01%), a mild-to-moderate topical corticosteroid, suppresses melanocyte inflammation and counteracts the irritant dermatitis of hydroquinone and tretinoin. Indicated for the short-term moderate-to-severe melasma of the face.

Mometasone Furoate (0.1% w/w cream/ointment) is a high-potency (Class II) synthetic topical corticosteroid on the WHO Model List of Essential Medicines. It features a high therapeutic index, providing robust anti-inflammatory and anti-pruritic activity with significantly lower systemic absorption and cutaneous atrophogenic potential than older fluorinated steroids. Indicated for relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, including atopic dermatitis and psoriasis.

Mometasone Furoate Aqueous Nasal Spray (0.05% w/v / 50mcg per actuation) is a topically active synthetic glucocorticoid on the WHO Model List of Essential Medicines. It exhibits high topical anti-inflammatory potency on nasal mucosa with undetectable systemic bioavailability (<0.1%), downregulating pro-inflammatory cytokines and allergic cellular infiltration. Indicated for treatment and prophylaxis of seasonal and perennial allergic rhinitis in adults and children >=2 years, and treatment of nasal polyps in adults >=18 years.

Indacaterol (150mcg) and Mometasone Furoate (80mcg/160mcg/320mcg Powder for Inhalation) is an advanced once-daily LABA and inhaled corticosteroid combination. Indacaterol is an ultra-long-acting beta-2 agonist (ultra-LABA) providing 24-hour bronchodilator coverage from a single dose; mometasone furoate provides powerful glucocorticoid anti-inflammatory action with negligible systemic oral bioavailability (<1%). Indicated for once-daily maintenance treatment of asthma in adults and adolescents inadequately controlled with ICS/LABA combinations.

Indacaterol (150mcg) and Mometasone Furoate (80mcg/160mcg/320mcg Powder for Inhalation) is an advanced once-daily LABA and inhaled corticosteroid combination. Indacaterol is an ultra-long-acting beta-2 agonist (ultra-LABA) providing 24-hour bronchodilator coverage from a single dose; mometasone furoate provides powerful glucocorticoid anti-inflammatory action with negligible systemic oral bioavailability (<1%). Indicated for once-daily maintenance treatment of asthma in adults and adolescents inadequately controlled with ICS/LABA combinations.

Indacaterol (150mcg) and Mometasone Furoate (80mcg/160mcg/320mcg Powder for Inhalation) is an advanced once-daily LABA and inhaled corticosteroid combination. Indacaterol is an ultra-long-acting beta-2 agonist (ultra-LABA) providing 24-hour bronchodilator coverage from a single dose; mometasone furoate provides powerful glucocorticoid anti-inflammatory action with negligible systemic oral bioavailability (<1%). Indicated for once-daily maintenance treatment of asthma in adults and adolescents inadequately controlled with ICS/LABA combinations.

Nadifloxacin (1% w/w cream) is a synthetic broad-spectrum fluoroquinolone bactericidal antibacterial agent for topical dermatological use. It inhibits bacterial DNA gyrase (topoisomerase II), blocking bacterial DNA replication against Cutibacterium acnes, Staphylococcus epidermidis, and methicillin-resistant S. aureus (MRSA). Indicated for acne vulgaris, folliculitis, and superficial bacterial skin infections.